A new national study of MDMA deaths has put hard numbers on an awkward point for drug checking. Much of the risk sits outside the pill, in the body that takes it and in everything else taken alongside it.
Researchers at the National Drug and Alcohol Research Centre at UNSW Sydney examined 217 deaths recorded between 2016 and 2025 in the National Coronial Information System. The findings appear in the journal Addiction. Trend analysis stops at 2023, because coroners had closed only 51.7 per cent of 2024 cases and 25 per cent of 2025 cases. Within that window, the death rate climbed steeply until 2019 and then fell by roughly 27 per cent a year. The authors add that the confidence intervals were wide.
Most deaths involve a mix of drugs, not one pill
In 179 of the 217 cases, or 82.5 per cent, coroners attributed death to multiple drug toxicity. Just 38 deaths came down to MDMA alone. Other psychoactive drugs turned up in 199 cases (91.7 per cent). Other stimulants appeared in 67.7 per cent, including cocaine in 38.2 per cent and methamphetamine in 36.4 per cent. Opioids featured in 45.2 per cent, and alcohol in 33.2 per cent.
The paper does not say how much of that came from the same tablet. Even so, the limit of drug checking is plain. A test examines a sample of one pill. It cannot see a line of cocaine, a night of drinking or an opioid already in someone’s system. The authors describe mixing MDMA with other stimulants as a particularly risky pattern of use.
Earlier national research points the same way. An information sheet summarising a study of 392 MDMA related deaths between 2000 and 2018 reports that 48 per cent involved polydrug use. It records no deaths from contaminants or impurities in pills. Pills mixed with PMA accounted for 3 per cent, and a variety of other drugs for another 3 per cent.
The risk lives in the person, not only the pill
Pathologists examined the heart in 199 cases. They found an enlarged heart in 33 (16.6 per cent) and severe coronary artery disease in 27 (13.6 per cent). The average age of those who died was 33.5. The authors call these high levels for such a young group. Sudden collapse (17.1 per cent), hyperthermia (12.9 per cent) and cardiac arrest (12.4 per cent) were the most commonly recorded signs at the fatal incident.
The 1995 death of 15 year old Anna Wood, Australia’s first recorded ecstasy death, shows the problem for drug checking. According to the information sheet, her pill contained no impurities or adulterants, and four friends who took pills from the same batch survived. On that account, a laboratory check of the tablet would have found nothing to warn her about.
Dose offers little comfort either. The sheet cites a South Australian study of 49 MDMA users, none of whom died. Among those who took 100 to 115 mg, peak blood levels varied tenfold, from 120 to 1040 ng/mL. By comparison, the median blood concentration in the coronial study was 0.41 mg/L, which equals 410 ng/mL. The sheet’s reading is that the milligrams in a pill cannot predict whose blood will reach a toxic level. It also cites rodent research in which rats given a fifth of a lethal dose all died once the room warmed from 22 to 29 degrees Celsius.
Why drug checking misses where people die
Only 16 deaths (7.4 per cent) occurred at a music festival. In contrast, 171 (78.8 per cent) happened in a private setting such as a home or hotel room, and 61 people (28.1 per cent) were alone when they died. Another 30 deaths took place in public spaces such as bars and streets. A drug checking service operating at an event, however well run, reaches a sliver of that picture.
Meanwhile, 101 people (46.5 per cent) received medical intervention before they died. That figure points to the value of spotting overheating, collapse and seizure early. The authors say so directly, and they warn that using MDMA alone can be a dangerous practice.
A green light that can backfire
Pill Testing Australia’s classification, reproduced in the information sheet, gives a white card when a sample matches what the patron expected. A red card goes to substances linked with increased harm, overdoses or death. A pill containing only MDMA therefore earns a white card. The sheet notes that MDMA was in 90 per cent of the 158 pills tested in Canberra in 2019. The red cards went to seven pills containing a different stimulant.
The Australian National University evaluation, as quoted in the sheet, found that most patrons already had an accurate idea of what they had bought. However, those who received confirmation were “likely to take as much or more than originally intended.” In other words, pill testing told people little they did not know and may have nudged their use upward.
What the authors recommend and what the figures show
In fairness, the study authors do say buyers would be prudent to use a drug checking service where one exists, citing evidence of adulteration. They also stress that people who use MDMA need to understand its effects on the heart, the dangers of combining it with other stimulants, and the need for immediate medical help when someone overheats, collapses or has a seizure.
Yet the data back those warnings far more strongly than they back drug checking. Adulteration, the main argument for testing, accounts for a small minority of deaths in the earlier national study. The authors link the fall in deaths after 2019 to reports of lower MDMA availability and purity during COVID, although they did not test that link. They do not attribute it to any testing service.
A drug checking result tells a person what is in a tablet. The coroners’ files suggest that is rarely what decides who survives the night. Hearts, heat, company and combinations all play a part. The surest way to avoid every risk in these files is not to take the drug at all.
Dalgarno Institute
Sources: